Sulindac sulfone
产品说明书
 |
同义名 : | - |
| CAS号 : | 59973-80-7 | |
| 货号 : | A1161164 | |
| 分子式 : | C20H17FO4S | |
| 纯度 : | 97% | |
| 分子量 : | 372.41 | |
| MDL号 : | MFCD00871143 | |
| 存储条件： |
Pure form Sealed in dry, room temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Sulindac sulfone is a metabolite of sulindac, a non-steroidal anti-inflammatory drug (NSAID), without anti-inflammatory ability. VDAC1 and VDAC2 (voltage-dependent anion channel) are direct targets of sulindac sulfone which suppresses the mTORC1 pathway and induces G1 arrest[1]. At 100 microMol of sulindac sulfone, a decrease in beta-catenin concentration of 5% was observed; increasing concentrations of sulindac sulfone resulted in >70% reduction in secreted beta-catenin. Sulindac sulfone reduced levels of secreted beta-catenin in the HNSCC (head and neck squamous cell carcinoma) cell line UM-SCC 11A after 48 hours of incubation[2]. Sulindac sulfone inhibited COX-2 (cyclooxygenase) protein expression, which resulted in a decrease in prostaglandin synthase E2 production[3]. Sulindac (20 mg/kg/day), sulindac sulfone (40 mg/kg/day), or vehicle was administered orally to male Sprague-Dawley rats for a 4-wk period beginning 20 wk after tumor induction. Sulindac and sulindac sulfone treatment significantly reduced the number and volume of colorectal tumors compared with control rats[4]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.69mL 0.54mL 0.27mL |
13.43mL 2.69mL 1.34mL |
26.85mL 5.37mL 2.69mL |
| 参考文献 |
|---|